JG
TVTX icon

Jefferies Group’s Travere Therapeutics TVTX Stock Holding History

Jefferies Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-23,000
Closed -$267K – 3019
2019
Q3 		$267K Sell
23,000
-27,300
-54% -$451K ﹤0.01% 2236
2019
Q2 		$1.01M Sell
50,300
-159,800
-76% -$3.16M 0.01% 1293
2019
Q1 		$4.75M Buy
+210,100
New +$4.64M 0.04% 459
2016
Q3 		– Sell
-28,500
Closed -$508K – 2456
2016
Q2 		$508K Sell
28,500
-121,500
-81% -$1.97M ﹤0.01% 1444
2016
Q1 		$2.05M Buy
+150,000
New +$2.28M 0.01% 829

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jefferies Group's TVTX Position: Q3 2020 in Review

Jefferies Group sold out of Travere Therapeutics (TVTX) in Q3 2020, closing a stake of 25,000 shares — an estimated $510 sold.

Jefferies Group first reported a position in TVTX in Q1 2016 and held it in 9 quarters. The position peaked at $1.44M in Q3 2018. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

  • Jefferies Group reported no remaining Travere Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Jefferies Group sold 25,000 Travere Therapeutics shares in Q3 2020, an estimated $510.
  • Jefferies Group first reported a position in Travere Therapeutics in Q1 2016 and held it in 9 quarters.
  • Jefferies Group's Travere Therapeutics position peaked at $1.44M in Q3 2018.
  • 134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.